Brokers Issue Forecasts for BCAX FY2026 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – HC Wainwright issued their FY2026 earnings estimates for Bicara Therapeutics in a research report issued to clients and investors on Wednesday, November 11th. HC Wainwright analyst R. Burns expects that the company will earn ($3.86) per share for the year. HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($3.82) per share. HC Wainwright also issued estimates for Bicara Therapeutics’ Q4 2026 earnings at ($1.07) EPS.

BCAX has been the topic of several other research reports. Stifel Nicolaus cut their price target on Bicara Therapeutics from $45.00 to $43.00 and set a “buy” rating on the stock in a report on Tuesday. Wall Street Zen downgraded Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 31st. Wells Fargo & Company increased their target price on Bicara Therapeutics from $16.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 12th. Morgan Stanley cut their target price on Bicara Therapeutics from $41.00 to $30.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, Citigroup reissued a “market outperform” rating on shares of Bicara Therapeutics in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $30.33.

Bicara Therapeutics Trading Down 4.0%

NASDAQ:BCAX opened at $10.11 on Friday. The firm has a market capitalization of $671.20 million, a PE ratio of -2.91 and a beta of -0.33. The stock has a 50 day moving average of $17.10 and a 200-day moving average of $20.81. Bicara Therapeutics has a 52 week low of $7.87 and a 52 week high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Monday, November 9th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.22).

Institutional Trading of Bicara Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its position in Bicara Therapeutics by 33.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 44,425 shares of the company’s stock valued at $827,000 after buying an additional 11,086 shares in the last quarter. Nan Fung Trinity HK Ltd. increased its stake in Bicara Therapeutics by 49.9% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 427,885 shares of the company’s stock valued at $7,963,000 after buying an additional 142,390 shares during the period. Alps Advisors Inc. increased its stake in Bicara Therapeutics by 32.5% during the 3rd quarter. Alps Advisors Inc. now owns 87,692 shares of the company’s stock valued at $1,632,000 after buying an additional 21,510 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Bicara Therapeutics during the 3rd quarter worth about $63,000. Finally, Profund Advisors LLC raised its position in shares of Bicara Therapeutics by 7.2% during the 3rd quarter. Profund Advisors LLC now owns 16,880 shares of the company’s stock worth $314,000 after buying an additional 1,140 shares in the last quarter.

Insider Transactions at Bicara Therapeutics

In related news, CEO Ryan Cohlhepp sold 17,500 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total value of $400,750.00. Following the completion of the transaction, the chief executive officer directly owned 181,641 shares of the company’s stock, valued at $4,159,578.90. This represents a 8.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is owned by company insiders.

Latest Bicara Therapeutics News

Here’s some of the latest news about BCAX:

• Positive Sentiment: HC Wainwright kept its Buy rating on BCAX and a $36 price target, which could support investor optimism despite the target reduction from $42. HC Wainwright target update
• Negative Sentiment: Stifel Nicolaus and Morgan Stanley reportedly cut their BCAX price targets, and BTIG Research issued a pessimistic forecast. These actions may weigh on sentiment; the provided headlines do not specify the revised targets or detailed rationale. Stifel target cut Morgan Stanley target cut BTIG forecast
• Negative Sentiment: HC Wainwright’s 2027 estimates project continuing quarterly losses, including a full-year loss of $4.63 per share. Expectations of ongoing losses can be a headwind for a clinical-stage biotech, even with the firm’s Buy rating.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.